Primary Open Angle Glaucoma - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Primary Open Angle Glaucoma – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Primary Open Angle Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Primary Open Angle Glaucoma: Overview
Primary open-angle glaucoma is a syndrome of optic nerve damage associated with an open anterior chamber angle and an elevated or sometimes average intraocular pressure (IOP). The most common symptom is the visual field loss. Diagnosis of Primary Open Angle Glaucoma is usually done by ophthalmoscopy, gonioscopy, visual field examination, and measurement of central corneal thickness and IOP. Treatment options includes topical drugs and often requires laser or incisional surgery to increase aqueous drainage.
'Primary Open Angle Glaucoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wilson’s Disease pipeline landscape is provided which includes the disease overview and Primary Open Angle Glaucoma treatment guidelines. The assessment part of the report embraces, in depth Primary Open Angle Glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Open Angle Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Primary Open Angle Glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve Primary Open Angle Glaucoma.
Primary Open Angle Glaucoma Emerging Drugs Chapters
This segment of the Primary Open Angle Glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Primary Open Angle Glaucoma Emerging Drugs
PRO-122: Laboratorios Sophia S.A de C.V.
PRO-122 a novel Alpha 2 adrenergic receptor agonists being developed as an ophthalmic solution and is being studied in phase III for the development of primary open glaucoma by Laboratorios Sophia S.A de C.V.
DE-126: Santen Pharmaceuticals
DE-126 is a prostaglandin eye drop drug product with a novel, mode of action that is both FP and EP3 receptors dual agonist. DE-126 is expected to show a superior intraocular pressure lowering effect compared to tafluprost, an FP receptor agonist. Santen Pharmaceutical initiated the enrolment in a phase II trial for Open angle glaucoma and Ocular hypertension in USA.
Further product details are provided in the report……..
Primary Open Angle Glaucoma: Therapeutic Assessment
This segment of the report provides insights about the different Primary Open Angle Glaucoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Primary Open Angle Glaucoma
There are approx. 10+ key companies which are developing the therapies for Primary Open Angle Glaucoma. The companies which have their Primary Open Angle Glaucoma drug candidates in the most advanced stage, i.e. phase III include Laboratorios Sophia S.A de C.V.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Primary Open Angle Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Primary Open Angle Glaucoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Open Angle Glaucoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Open Angle Glaucoma drugs.
Primary Open Angle Glaucoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Primary Open Angle Glaucoma – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Primary Open Angle Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Primary Open Angle Glaucoma: Overview
Primary open-angle glaucoma is a syndrome of optic nerve damage associated with an open anterior chamber angle and an elevated or sometimes average intraocular pressure (IOP). The most common symptom is the visual field loss. Diagnosis of Primary Open Angle Glaucoma is usually done by ophthalmoscopy, gonioscopy, visual field examination, and measurement of central corneal thickness and IOP. Treatment options includes topical drugs and often requires laser or incisional surgery to increase aqueous drainage.
'Primary Open Angle Glaucoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wilson’s Disease pipeline landscape is provided which includes the disease overview and Primary Open Angle Glaucoma treatment guidelines. The assessment part of the report embraces, in depth Primary Open Angle Glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Open Angle Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Primary Open Angle Glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve Primary Open Angle Glaucoma.
Primary Open Angle Glaucoma Emerging Drugs Chapters
This segment of the Primary Open Angle Glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Primary Open Angle Glaucoma Emerging Drugs
PRO-122: Laboratorios Sophia S.A de C.V.
PRO-122 a novel Alpha 2 adrenergic receptor agonists being developed as an ophthalmic solution and is being studied in phase III for the development of primary open glaucoma by Laboratorios Sophia S.A de C.V.
DE-126: Santen Pharmaceuticals
DE-126 is a prostaglandin eye drop drug product with a novel, mode of action that is both FP and EP3 receptors dual agonist. DE-126 is expected to show a superior intraocular pressure lowering effect compared to tafluprost, an FP receptor agonist. Santen Pharmaceutical initiated the enrolment in a phase II trial for Open angle glaucoma and Ocular hypertension in USA.
Further product details are provided in the report……..
Primary Open Angle Glaucoma: Therapeutic Assessment
This segment of the report provides insights about the different Primary Open Angle Glaucoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Primary Open Angle Glaucoma
There are approx. 10+ key companies which are developing the therapies for Primary Open Angle Glaucoma. The companies which have their Primary Open Angle Glaucoma drug candidates in the most advanced stage, i.e. phase III include Laboratorios Sophia S.A de C.V.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Primary Open Angle Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
Products have been categorized under various Molecule types such as
- Bispecific Antibody
- Peptides
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Primary Open Angle Glaucoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Open Angle Glaucoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Open Angle Glaucoma drugs.
Primary Open Angle Glaucoma Report Insights
- Primary Open Angle Glaucoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Primary Open Angle Glaucoma drugs?
- How many Primary Open Angle Glaucoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Open Angle Glaucoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Primary Open Angle Glaucoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Primary Open Angle Glaucoma and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Primary Open Angle Glaucoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Primary Open Angle Glaucoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Primary Open Angle Glaucoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Primary Open Angle Glaucoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
PRO-122: Laboratorios Sophia S.A de C.V.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DE-126: Santen Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
WB-007: Whitecap Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Primary Open Angle Glaucoma Key Companies
Primary Open Angle Glaucoma Key Products
Primary Open Angle Glaucoma- Unmet Needs
Primary Open Angle Glaucoma- Market Drivers and Barriers
Primary Open Angle Glaucoma- Future Perspectives and Conclusion
Primary Open Angle Glaucoma Analyst Views
Primary Open Angle Glaucoma Key Companies
Appendix
Executive Summary
Primary Open Angle Glaucoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Primary Open Angle Glaucoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Primary Open Angle Glaucoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Primary Open Angle Glaucoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
PRO-122: Laboratorios Sophia S.A de C.V.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DE-126: Santen Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
WB-007: Whitecap Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Primary Open Angle Glaucoma Key Companies
Primary Open Angle Glaucoma Key Products
Primary Open Angle Glaucoma- Unmet Needs
Primary Open Angle Glaucoma- Market Drivers and Barriers
Primary Open Angle Glaucoma- Future Perspectives and Conclusion
Primary Open Angle Glaucoma Analyst Views
Primary Open Angle Glaucoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Primary Open Angle Glaucoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Primary Open Angle Glaucoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Primary Open Angle Glaucoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Primary Open Angle Glaucoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
